TOP1362 is a Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. TOP1362 strongly inhibited the kinase targets p38α, Syk, Src, and Lck, blocked the rise in p38α expression in hyperosmolar Chang cells, and potently reduced inflammatory cytokine release in cellular models of innate and adaptive immunities. In the EIU model, TOP1362 dose-dependently attenuated the LPS-induced rise in inflammatory cell infiltration and ocular cytokine levels with efficacy comparable to that of dexamethasone. References: Hagan S, Fyfe MCT, Ofori-Frimpong B, Oliver K, Foster MR, Sirohi S, Solanke Y, Doughty M, Rowley A, Taylor M, Webber S, Walshe CA. Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders. Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1443-1453. doi: 10.1167/iovs.17-23479. PubMed PMID: 29625466.

纯度：≥98%

CAS：1630203-25-6